Economic Forecast for Preclinical CROs

Economic Forecast for Preclinical CROs

Research and development (R&D), as well as manufacturing, are often outsourced from big pharma to smaller contract research organizations (CRO) with more resources and specialized expertise. As the global pharmaceutical market grows, so too does the need for contract service providers. Market research reports indicate a trend toward increasing capital spent on contract services, with a projected annual expenditure of $56.24 billion by 2023 (up $17.04 billion from $39.13 billion in 2018).

Therefore, it’s no surprise that contract research services are expected to maintain their dominance in the market. In fact, the industry may even gain ground in emerging countries like Brazil, Russia, India, and China, where there are few facilities and the field is still in its infancy. With increased R&D spending and a growing demand for outsourcing, CROs are being advised to position themselves for a boom in business.

The preclinical research sector alone, where results of animal testing determine whether a drug should advance to clinical trials, is predicted to reach $6.6 billion by 2025. TransPharm Preclinical Solutions will help you navigate this period of your project from beginning to end. We are an AAALAC-accredited, full-service CRO specializing exclusively in microbiology and preclinical infectious disease research. Send us your novel antimicrobial therapeutics, and we will perform efficacy testing using a study design customized to fit your needs. Our extensive experience running in vitro assays and in vivo disease models makes us the best option for your preclinical needs. Infectious disease research is all we do and no one does it better. But don’t take our word for it! Read testimonials from our satisfied clients all around the globe, and contact us to request a free, no-obligation quote.

Contact Us

9 + 12 =

Jackson Certified
Brooklyn-Irish Hills Chamber of Commerce logo